Bringing the fundamentals into focus…
Back to Regeneron Pharmaceuticals, Inc.
How Regeneron Pharmaceuticals, Inc. stacks up
REGN · against 37 other Healthcare companies of similar size
Valuation
61/ 100
Below the middle of the pack.
Ranked #21 of 38 · scores higher than 46% of peers
Bars: peers in each 10-point band of the valuation score7 peers with a valuation score of 60–69, including REGN · Click a bar to see the companies
Why valuation scores 61?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its earnings yield and free cash flow yield, which are stronger than most Healthcare peers.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.5% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 71% of peers. Free cash flow yield: 3.6% vs peer median 0.0%
- higher earnings for the price paid: stronger than 72% of peers. Earnings yield: 4.2% vs peer median 1.5%
Metric by metric
Position: dot = REGN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | REGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 37 reported | 4.1% | 3.7% | 64% | 30% | |
| EBITDA yieldHigher is better · 39 reported | 5.1% | 6.6% | 29% | 50% | |
| Free cash flow yieldHigher is better · 30 reported | 3.6% | 4.4% | 34% | 20% | |
| Book yieldHigher is better · 37 reported | 32.5% | 22.1% | 61% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around REGN| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 177.5B USD | 92 | 71 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 108.6B USD | 88 | 66 | |
| 4 | 97.5B USD | 87 | 67 | |
| 5 | 126.1B USD | 83 | 62 | |
| 17 | 171.0B USD | 66 | 45 | |
| 18 | 50.2B USD | 64 | 49 | |
| 19 | 116.5B USD | 63 | 57 | |
| 20 | 84.5B EUR (≈$92.9B) | 62 | 51 | |
| 21 | 100.2B USD | 61 | 68 | |
| 22 | 119.1B USD | 59 | 57 | |
| 23 | 58.6B USD | 58 | 52 | |
| 24 | 8.24T JPY (≈$56.0B) | 57 | 75 | |
| 24 | 189.3B USD | 57 | 45 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score